[Tickers Inside] 7 Solid Gainers Over the Last 5 Sessions

Stocks with 5 days of consecutive price advances. --------------------------------------------------------------- [Investors See Opportunity in Huge Global Demand for Lithium]( [Put this company on your investing radar today.](=) --------------------------------------------------------------- October 6, 2022 From the desk of the Editor (5 Day Gainers Report) Dear Reader, We just identified 7 Five Day Gainers of all US Exchanges. If you are interested in any of these companies, we encourage you to do your own research and due diligence. Keep reading to see what we just uncovered... --------------------------------------------------------------- [The Humble Mineral at the Heart of the EV Revolution (Not Lithium)]() You may know of graphite as what's in the tip of a No. 2 pencil, but it is the key to many forms of renewable energy. Today, this humble mineral is at the epicenter of the electric car revolution. Because what most people don't know is today's EV batteries contain more than 220 pounds of graphite ñ more than lithium, copper or aluminum! [Get the Full Story On This New American Graphite Opportunity.]() = --------------------------------------------------------------- [Senti Biosciences, SNTI]() Recent Analyst Action: Greg Harrison, analyst at Bank of America Securities, reiterates coverage on [Senti Biosciences (SNTI)](in the Healthcare sector with a Buy rating and a price target of $7.00 (1 week ago). - Recent Price: $6.52 - Average Analyst Price Target: $7.00 (7.36%) - Market Cap: $261.40M [TipRanks.com]() also reports that [Senti Biosciences]()currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $7.00. The target pricing ranges from a high forecast of $7.00 down to a low forecast of $7.00. [Senti Biosciences (SNTI)](=)’s last closing price was $6.52 which would put the average price target at $7.00. Here are 3rd party ratings for [SNTI](=): - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Hold, Top 23% (58 out of 251) [Click here for chart >>]() -------------------------------------------------------------------------- --------------------------------------------------------------- [#1 Stock for Energy Crisis (Buy Now for Just $8)](=) =As the world suffers an oil shock… And gas prices rip higher… One tiny company could have the answer to the global energy crisis. It’s using AI to crack open the largest untapped energy source on the planet… 5X larger than the biggest oil field on Earth. [Act fast, this $8 stock could be moments away from appreciating considerably.]( = --------------------------------------------------------------- [Immunovant, IMVT]( Recent Analyst Action: Douglas Tsao, analyst at H.C. Wainwright, reiterates coverage on [Immunovant (IMVT)](in the Healthcare sector with a Buy rating (1 week ago). - Recent Price: $9.82 - Average Analyst Price Target: $8.75 (-10.90%) - Market Cap: $1.09B [TipRanks.com]() also reports that [Immunovant]()currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $8.75. The target pricing ranges from a high forecast of $12.00 down to a low forecast of $5.00. [Immunovant (IMVT)](’s last closing price was $9.82 which would put the average price target at $8.75. Here are 3rd party ratings for [IMVT](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 23% (58 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- [Cepton, CPTN]( Recent Analyst Action: Samik Chatterjee, analyst at J.P. Morgan, reiterates coverage on [Cepton (CPTN)]()in the Technology sector with a Hold rating (2 weeks ago). - Recent Price: $2.68 - Average Analyst Price Target: $3.25 (21.27%) - Market Cap: $384.35M [TipRanks.com]() also reports that [Cepton](currently has 4 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $3.25. The target pricing ranges from a high forecast of $4.00 down to a low forecast of $2.00. [Cepton (CPTN)](’s last closing price was $2.68 which would put the average price target at $3.25. Here are 3rd party ratings for [CPTN](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Hold, Bottom 42% (145 out of 251) [Click here for chart >>]() -------------------------------------------------------------------------- --------------------------------------------------------------- [Get Expert Stock Recommendations for Just $1](=) =See what some of the smartest minds in the financial world are buying today for just $1. Gains as high as 834%,1,315%, and 1,601% [already uncovered!](=) = --------------------------------------------------------------- [Roivant Sciences, ROIV]( Recent Analyst Action: Douglas Tsao, analyst at H.C. Wainwright, reiterates coverage on [Roivant Sciences (ROIV)](in the Healthcare sector with a Buy rating (1 week ago). - Recent Price: $4.53 - Average Analyst Price Target: $12.00 (164.90%) - Market Cap: $2.86B [TipRanks.com](=) also reports that [Roivant Sciences](=)currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $12.00. The target pricing ranges from a high forecast of $16.00 down to a low forecast of $7.00. [Roivant Sciences (ROIV)](’s last closing price was $4.53 which would put the average price target at $12.00. Here are 3rd party ratings for [ROIV](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Sell, Top 23% (58 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- [Provention Bio, PRVB]( Recent Analyst Action: Geulah Livshits, analyst at Chardan Capital, reiterates coverage on [Provention Bio (PRVB)](in the Healthcare sector with a Buy rating (21 hours ago). - Recent Price: $6.22 - Average Analyst Price Target: $12.50 (100.96%) - Market Cap: $403.67M [TipRanks.com]() also reports that [Provention Bio](currently has 6 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $12.50. The target pricing ranges from a high forecast of $18.00 down to a low forecast of $8.00. [Provention Bio (PRVB)](’s last closing price was $6.22 which would put the average price target at $12.50. Here are 3rd party ratings for [PRVB](: - TipRanks.com: Strong Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Buy, Top 23% (58 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush."]() Experts predict that the global lithium market will balloon by 500%. That's wonderful news for investors, because a "sure-thing" like this appears once in a lifetime. And this small-cap company just snagged what could be one of the world's largest lithium deposits. [Discover This Company's MASSIVE Lithium Opportunity!]( --------------------------------------------------------------- [Gracell Biotechnologies, GRCL](=) Recent Analyst Action: Nick Abbott, analyst at Wells Fargo, reiterates coverage on [Gracell Biotechnologies (GRCL)]()in the Healthcare sector with a Buy rating and a price target of $7.00 (1 month ago). - Recent Price: $3.52 - Average Analyst Price Target: $7.00 (98.86%) - Market Cap: $240.32M [TipRanks.com]() also reports that [Gracell Biotechnologies]()currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $7.00. The target pricing ranges from a high forecast of $7.00 down to a low forecast of $7.00. [Gracell Biotechnologies (GRCL)]()’s last closing price was $3.52 which would put the average price target at $7.00. Here are 3rd party ratings for [GRCL](=): - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Buy, Top 23% (58 out of 251) [Click here for chart >>]() -------------------------------------------------------------------------- [Permian Resources, PR](=) Recent Analyst Action: Zach Parham, analyst at J.P. Morgan, reiterates coverage on [Permian Resources (PR)](=)in the Utilities sector with a Buy rating and a price target of $12.00 (3 weeks ago). - Recent Price: $9.03 - Average Analyst Price Target: $10.86 (20.27%) - Market Cap: $2.45B [TipRanks.com](=) also reports that [Permian Resources](currently has 8 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $10.86. The target pricing ranges from a high forecast of $13.00 down to a low forecast of $7.00. [Permian Resources (PR)](=)’s last closing price was $9.03 which would put the average price target at $10.86. Here are 3rd party ratings for [PR](=): - TipRanks.com: Strong Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: buy - Zacks.com: Strong Buy, Top 9% (22 out of 251) [Click here for chart >>](=) -------------------------------------------------------------------------- --------------------------------------------------------------- [The Lithium "Lie"]() Did you know each electric car battery requires 220 pounds of graphite ñ more than lithium, copper, or aluminum? China controls more than 90% of this vital ingredient. But the U.S. just classified graphite as "essential for America's National Defense"... and one little-known company is looking to win big in the energy war with China. [Find Out How Investors Can Benefit From the Energy War with China]() --------------------------------------------------------------- And there you have it--7 Five Day Gainers of all US Exchanges. Sincerely, The Editor, MarketSectorDaily.com [Unsubscribe]( Sandpiper Marketing Group, LLC PO Box 407 Mt. Mourne, North Carolina 28123 United States (845) 803-0954 If you no longer wish to receive our emails, click the link below: [Unsubscribe]( MarketSectorDaily.com part of Sandpiper Marketing Group, LLC 165 Lockerbie Lane Mooresville, North Carolina 28115 United States (877) 411-9808